Skip To Main Content
ThromboGenics NV on Muck Rack

ThromboGenics NV

As seen in: Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with ThromboGenics

Contact ThromboGenics, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: 17-05-2017]

|
By ThromboGenics NV
| bioportfolio.co.uk
ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT).
Open in Who Shared Issue with article?

ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: 22-03-2017]

|
By ThromboGenics NV
| bioportfolio.co.uk
ThromboGenics NV (ThromboGenics) is a biopharmaceutical company which develops and commercializes ophthalmic and oncology medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and in Denmark, Sweden, and Germany and the UK to treat vitreomacular traction (VMT).
Open in Who Shared Issue with article?

Robotic Assisted Cannulation of Occluded Retinal Veins

|
By ThromboGenics NV, Preceyes nv, Tom Janssens, Valerie Vanheukelom
| PLOS
To develop a methodology for cannulating porcine retinal venules using a robotic assistive arm after inducing a retinal vein occlusion using the photosensitizer rose bengal. Retinal vein occlusions proximal to the first vascular branch point were induced following intravenous injection of rose bengal by exposure to 532nm laser light delivered by slit-lamp or endolaser probe.
Open in Who Shared Issue with article?
See all 4 articles